AHA · Chicago · 2026-11-06 – 2026-11-09
AHA Scientific Sessions 2026
1 of 21 Late-Breaking Science trials with a resultResults are embargoed until each presentation and appear here as they are released.
Fri, Nov 6
Sat, Nov 7
LBS.01 The Dr. Eugene Braunwald Late-Breaking Science Session: Translating Science into Prevention: Lessons from Landmark Trials
08:35–09:50 (America/Chicago) · Center Stage, North Hall, Level 3- 08:35ZEUSClinical studyPrimary Report of the Ziltivekimab Cardiovascular Outcomes Trial (ZEUS)Presentation Sat, 08:35
- 08:50Lp(a)HORIZON CoreCardiology · Lipids · Lipoprotein(a)In 8,323 patients with established cardiovascular disease and Lp(a) ≥70 mg/dL, pelacarsen 80 mg monthly did not reduce cardiovascular death, myocardial infarction, stroke or urgent revascularisation compared with placebo.Read →
- 09:00Lp(a)HORIZON extended analysesObservational studyExtended Analyses of Cardiovascular Outcomes With Pelacarsen Treatment in the Lp(a)Horizon TrialPresentation Sat, 09:00
LBS.02 Late-breaking Science: Treating the Clot or Controlling the Blood Pressure: Improving Outcomes After Stroke
13:45–14:45 (America/Chicago) · Center Stage, North Hall, Level 3- 13:45OCEANIC-STROKE FraminghamObservational studyOutcomes in the OCEANIC-STROKE Randomized, Placebo-Controlled Trial: FXIa Inhibition by Asundexian in Participants With Non-Cardioembolic Stroke or Transient Ischemic Attack by Non-Laboratory Framingham Risk Score CategoryPresentation Sat, 13:45
- 14:00REDUCEClinical studyA Randomized Controlled Trial of Spironolactone-Based Blood Pressure Management After StrokePresentation Sat, 14:00
- 14:15OPTIMAL-StrokeClinical studyIntensive Blood-Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Prior Stroke: The OPTIMAL-Stroke TrialPresentation Sat, 14:15
LBS.03 Late-breaking Science: Hot Topics in CVD Prevention
15:15–16:30 (America/Chicago) · Center Stage, North Hall, Level 3- 15:15STREAMClinical studyDiscontinuing Statins in Multimorbid Older Adults Without Cardiovascular Disease: A Randomized Non-Inferiority Clinical TrialPresentation Sat, 15:15
- 15:30OPTIMAL-DIABETESClinical studyIntensive Blood Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Type 2 Diabetes - The OPTIMAL-DIABETES TrialPresentation Sat, 15:30
- 15:45Ez-PAVEClinical studyStatin-Ezetimibe Combination Therapy versus Statin Monotherapy in Patients With Atherosclerotic Cardiovascular Disease: Pre-Specified Second Randomization of the Ez-PAVE TrialPresentation Sat, 15:45
- 16:00Yoga-CaRe HFClinical studyYoga-Based Cardiac Rehabilitation in Heart Failure With Reduced Ejection FractionPresentation Sat, 16:00
Sun, Nov 8
LBS.04 Late-breaking Science: Innovations to Optimize Arrhythmia Care
15:30–16:45 (America/Chicago) · Center Stage, North Hall, Level 3- 15:30OptimPacingClinical studyLeft Bundle Branch Pacing versus Right Ventricular Pacing for Atrioventricular Block: An International Multi-Center Randomized Controlled Trial (OptimPacing Study)Presentation Sun, 15:30
- 15:45COAST-AFClinical studyCharacterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation: COAST-AF Randomized TrialPresentation Sun, 15:45
- 16:00SUPERIORClinical studySacubitril/Valsartan for Preventing Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Hypertension: A Multicenter, Randomized Controlled TrialPresentation Sun, 16:00
- 16:15RACE-CARSClinical studyRandomized Cluster Evaluation of Cardiac ARrest Systems (RACE-CARS) Trial Primary ResultsPresentation Sun, 16:15
Mon, Nov 9
LBS.05 Late-breaking Science: New Frontiers in Cardiometabolic Risk Reduction
08:00–09:15 (America/Chicago) · Center Stage, North Hall, Level 3- 08:00TYDAL-TIMI 78Clinical studyTYDAL-TIMI 78: A Randomized Trial of ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol ConcentrationsPresentation Mon, 08:00
- 08:15CTX310Clinical studyCRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b TrialPresentation Mon, 08:15
- 08:30ATTAIN-OSAClinical studyOrforglipron for the Treatment of Obstructive Sleep Apnea: Results From Attain-OSAPresentation Mon, 08:30
- 08:45SYNCHRONIZE-CVOTClinical studySurvodutide and Cardiovascular Outcomes in Obesity: Results from the SYNCHRONIZE®-CVOT TrialPresentation Mon, 08:45
LBS.06 Late-breaking Science: Artificial Intelligence in the Diagnosis of Cardiovascular Disease
09:45–11:00 (America/Chicago) · Center Stage, North Hall, Level 3- 09:55WATCH-LVObservational studyConsumer Smartwatch Artificial Intelligence-Enabled Electrocardiogram for Left Ventricular Systolic Dysfunction: Cross-Manufacturer Validation and Serial Home MonitoringPresentation Mon, 09:55
- 10:05PROVAR+Observational studyAI-Enabled Tele-ECG Identifies Structural Heart Disease and Prioritizes Echocardiography in Underserved Populations: The PROVAR+ External Validation StudyPresentation Mon, 10:05
- 10:22AI echo interpretation RCTClinical studyAI-Assisted Comprehensive Echocardiographic Interpretation—A Blinded, Randomized Controlled TrialPresentation Mon, 10:22